Validation of a Predictive Risk Equation for Type 2 Diabetes in Families With Risk

NCT ID: NCT01727349

Last Updated: 2021-05-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

1035 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-12-14

Study Completion Date

2020-11-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Considering its epidemic-like development worldwide, associated with modifications in lifestyle, as well as its enormous social and economic weight, the prevention of type II diabetes is certain to be a central concern of health systems within the developed countries in the decades to come. However, while simple obesity concerns the entire population, type 2 diabetes affects only one sub-population at high genetic risk. To be effective and realistic in economic terms, efforts at prevention must be thus targeted towards these subjects at high risk. The key issue involves identifying such subjects early enough so that a strategy of effective prevention can be organized in good time.

Until now, efforts have been concentrated on individuals at risk for diabetes readily identifiable within the general population, typically subjects in the second half of adulthood, presenting abdominal obesity and mild abnormalities of blood sugar. Preventive lifestyle and dietary measures are proposed but are constrictive and difficult to maintain over time, and the results, although they may be significant, remain disappointing, with mere postponement of an outcome which at this stage appears inevitable. The reason is ascribable to excessively tardy intervention, when the pathogenic process has already been ongoing for some ten years and the endocrine function of the pancreas is probably already irreparably impaired.

The alternative thus is earlier intervention, in childhood, adolescence or early adulthood. The problem is to identify individuals at high risk of becoming diabetic at a time when they are presenting no simple clinical or laboratory abnormalities allowing easy diagnosis. The familial character of type 2 diabetes is now well established, and future diabetic subjects are themselves above all the children of diabetic subjects. However, the prevalence of the disease among the descendants of type 2 diabetic subjects is around 20-30% and predictive tools are needed to combat diabetes in these high-risk families.

We propose to create a risk equation using an algorithm to reliably predict children most likely to develop diabetes later in life.

The algorithm will include 3 classes of data:

* The genotype stemming from the genetic characterization of individuals and those their parents;
* Environmental data concerning childhood, especially eating habits and physical activity;
* Data of the mother who was eventually diabetic during pregnancy.

From a methodological standpoint, it would be rather difficult to take blood samples from children and wait some 50 years to determine whether or not they develop diabetes. To circumvent this difficulty, we will recruit subjects in families with a history of type II diabetes:

* Parents alive, including at least one type 2 diabetic subject
* Adult children (aged over 35 years), some of whom are already presenting type II diabetes, and healthy brothers and sisters, who form the control population. Test will be done to determine whether healthy subjects are really safe from the risk of diabetes (HbA1c measurement and glucose load test).

The Descendence study will include 500 families at risk involving about 3000 subjects (1000 subjects with diabetes and 2000 healthy subjects). It is expected to answer the following question: for a child born in such families at risk, what is the probability of developing diabetes later in life, so that early preventive action may be taken

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Type 2 diabetic subject

Subject with type 2 diabetes

Group Type OTHER

HbA1c measurement

Intervention Type OTHER

healthy subject

Healthy subjet from family where there is the existence of the disease (type 2 diabetes) in two successive generations

Group Type OTHER

Oral Glucoce Tolerance Test

Intervention Type OTHER

Oral Glucoce Tolerance Test

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HbA1c measurement

Intervention Type OTHER

Oral Glucoce Tolerance Test

Oral Glucoce Tolerance Test

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Families at risk for diabetes defined by the existence of the disease in two successive generations and consists with healthy subject in the two generations.
* Subjects must be aged over 25 years

Exclusion Criteria

* subject refusing to participate
* pregnant women
Minimum Eligible Age

25 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Sart Tilman Liège

Liège, , Belgium

Site Status

CHU Jean Minjoz

Besançon, , France

Site Status

CHU Avicenne

Bobigny, , France

Site Status

CHU de Bondy

Bondy, , France

Site Status

CHU de BREST

Brest, , France

Site Status

CHU de Caen

Caen, , France

Site Status

CH Sud Francilien

Évry, , France

Site Status

University Hospital Grenoble

Grenoble, , France

Site Status

CHU de Bicetre

Le Kremlin-Bicêtre, , France

Site Status

CHRU Lille

Lille, , France

Site Status

CHU Marseille Hôpitaux Sud

Marseille, , France

Site Status

CHU de Nancy

Nancy, , France

Site Status

CHU de Nantes

Nantes, , France

Site Status

CHU Bichat

Paris, , France

Site Status

CHU de REIMS

Reims, , France

Site Status

Centre Hospitalier Strasbourg

Strasbourg, , France

Site Status

CHU Toulouse

Toulouse, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2011-A00686-35

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.